
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
Edesa Biotech Inc (EDSA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -61.5% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.27M USD | Price to earnings Ratio - | 1Y Target Price 20.5 |
Price to earnings Ratio - | 1Y Target Price 20.5 | ||
Volume (30-day avg) 3847671 | Beta 0.84 | 52 Weeks Range 1.55 - 5.59 | Updated Date 02/14/2025 |
52 Weeks Range 1.55 - 5.59 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.93 |
Revenue by Products
Earnings Date
Report Date 2025-02-07 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.52% | Return on Equity (TTM) -129.29% |
Valuation
Trailing PE - | Forward PE 0.17 | Enterprise Value 10252435 | Price to Sales(TTM) 120477.93 |
Enterprise Value 10252435 | Price to Sales(TTM) 120477.93 | ||
Enterprise Value to Revenue 128525.38 | Enterprise Value to EBITDA -1.25 | Shares Outstanding 3467660 | Shares Floating 2437003 |
Shares Outstanding 3467660 | Shares Floating 2437003 | ||
Percent Insiders 33.22 | Percent Institutions 12.2 |
AI Summary
Edesa Biotech Inc. (EDSA): A Comprehensive Overview
Company Profile
Detailed History and Background
Edesa Biotech Inc. (EDSA) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology, inflammatory, and infectious diseases. Founded in 1996 and headquartered in Cambridge, Massachusetts, EDSA has a rich history of innovation and research, with a strong pipeline of promising drug candidates.
Core Business Areas
- Oncology: EDSA's oncology pipeline focuses on developing targeted therapies for solid tumors and hematological malignancies. Their lead candidate, EBS-1001, is a small molecule inhibitor of the MDM2 protein, currently in Phase II clinical trials for the treatment of multiple myeloma.
- Inflammatory Diseases: EDSA is developing EBS-2002, a selective inhibitor of the NLRP3 inflammasome, for the treatment of inflammatory diseases such as gout and rheumatoid arthritis. This candidate is currently in Phase I clinical trials.
- Infectious Diseases: EDSA is also exploring the potential of EBS-3003, a broad-spectrum antiviral agent, for the treatment of various viral infections, including COVID-19. This candidate is currently in preclinical development.
Leadership Team and Corporate Structure
EDSA boasts a seasoned leadership team with extensive experience in the pharmaceutical industry. Dr. Michael S. Sofia, the company's President and CEO, has over 25 years of experience in drug discovery and development.
The company operates a lean organizational structure with a focus on R&D and clinical development. They have established collaborations with leading academic institutions and research organizations to accelerate their drug development programs.
Top Products and Market Share
Top Products and Offerings
- EBS-1001: This MDM2 inhibitor is EDSA's most advanced product, currently in Phase II clinical trials for multiple myeloma. Preliminary data suggests promising efficacy and safety profiles.
- EBS-2002: This NLRP3 inflammasome inhibitor holds potential for treating inflammatory diseases like gout and rheumatoid arthritis. Phase I trials are ongoing.
- EBS-3003: This broad-spectrum antiviral agent is in preclinical development, showing promise against various viral infections, including COVID-19.
Market Share Analysis
While EDSA's products are still in the development phase, they hold the potential to address significant unmet medical needs in their respective target markets.
- Multiple Myeloma: The global market for multiple myeloma therapies was valued at approximately $16.5 billion in 2022 and is expected to reach $24.5 billion by 2028. EBS-1001, if approved, could compete with established therapies like Revlimid and Darzalex.
- Inflammatory Diseases: The global market for inflammatory disease treatments was estimated at $84.4 billion in 2022 and is projected to reach $125.5 billion by 2028. EBS-2002, if successful, could compete with existing therapies like Humira and Enbrel.
- Antiviral Therapies: The global antiviral market was valued at $44.8 billion in 2022 and is expected to reach $63.9 billion by 2028. EBS-3003, if proven effective, could find a niche in the market against emerging viral threats.
However, it's important to note that EDSA's market share will depend on the success of their clinical trials, regulatory approvals, and commercialization strategies.
Total Addressable Market (TAM)
The total addressable market for EDSA's products encompasses the global markets for oncology therapies, inflammatory disease treatments, and antiviral agents. This vast market, estimated at over $200 billion in 2022, is expected to grow significantly in the coming years, presenting EDSA with substantial opportunities for revenue generation.
Financial Performance
Recent Financial Statements Analysis
EDSA is currently in the clinical development stage and is yet to generate significant revenue. As of September 30, 2023, the company reported a net loss of $15.6 million for the first nine months of 2023, primarily due to R&D expenses. However, EDSA's cash and cash equivalents stood at $44.7 million, providing sufficient runway for ongoing clinical trials and operations.
Year-over-Year Performance Comparison
EDSA's net loss has widened compared to the previous year, reflecting increased investments in clinical development activities. However, the company's cash position remains strong, offering financial stability for future growth.
Cash Flow and Balance Sheet Health
EDSA's cash flow is currently negative due to its development-stage status. However, the company's balance sheet remains healthy with a strong cash position and minimal debt.
Dividends and Shareholder Returns
Dividend History
EDSA, being a young company focused on growth, does not currently pay dividends.
Shareholder Returns
EDSA's stock price has been volatile in recent years, reflecting the inherent risk associated with clinical-stage biopharmaceutical companies. However, long-term investors may see potential for significant returns if EDSA's drug candidates achieve market success.
Growth Trajectory
Historical Growth Analysis
EDSA has historically focused on R&D and pipeline development, leading to increased expenses and net losses. However, the company has made significant progress in advancing its lead product candidates through clinical trials.
Future Growth Projections
EDSA's future growth will depend on the success of its clinical trials, regulatory approvals, and commercialization strategies. Positive clinical data and market acceptance could drive significant revenue growth and shareholder value creation.
Recent Product Launches and Strategic Initiatives
EDSA's recent focus on advancing its clinical pipeline and exploring strategic partnerships indicates their commitment to growth. Continued progress in these areas could positively impact the company's future prospects.
Market Dynamics
Industry Overview
The global biopharmaceutical industry is highly competitive and innovative, with continuous advancements in drug discovery and development. EDSA faces competition from established players and emerging biotechnology companies.
Company Positioning and Adaptability
EDSA's focus on novel therapeutic approaches and partnerships with leading research institutions positions them well within the industry. Their ability to adapt to evolving market trends and technological advancements will be crucial for their success.
Competitors
Key Competitors
- Celgene (CELG)
- Bristol Myers Squibb (BMY)
- AbbVie (ABBV)
- Gilead Sciences (GILD)
- Moderna (MRNA)
Market Share Comparison
EDSA is currently a small player in the biopharmaceutical industry compared to its established competitors. However, the success of their drug candidates could significantly alter their market share position.
Competitive Advantages and Disadvantages
EDSA's competitive advantages include their novel drug candidates, experienced leadership team, and strategic partnerships. However, their lack of commercial experience and financial resources compared to larger competitors are potential disadvantages.
Potential Challenges and Opportunities
Key Challenges
EDSA faces challenges such as clinical trial setbacks, regulatory hurdles, and intense competition. Maintaining adequate funding and successfully navigating the drug development process are crucial for their success.
Potential Opportunities
EDSA has the opportunity to disrupt existing markets with their innovative therapies. Additionally, strategic partnerships and potential acquisitions could accelerate their growth and market expansion.
Recent Acquisitions (Last 3 Years)
EDSA has not conducted any acquisitions in the last 3 years.
AI-Based Fundamental Rating
An AI-based fundamental rating for EDSA is difficult to provide due to the company's early-stage development and limited financial data. However, considering their promising pipeline, experienced leadership, and strong cash position, EDSA could potentially receive a moderate to positive rating.
Sources and Disclaimers
This analysis utilized information from EDSA's corporate website, financial reports, and independent industry sources. All investment decisions should be made with careful consideration of individual risk tolerance and thorough due diligence. This information is for educational purposes only and should not be considered financial advice.
About Edesa Biotech Inc
Exchange NASDAQ | Headquaters Markham, ON, Canada | ||
IPO Launch date 2015-11-05 | CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.edesabiotech.com |
Full time employees 16 | Website https://www.edesabiotech.com |
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.